{"analyses":[{"ciLowerLimit":"1.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.40","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.017","paramType":"Odds Ratio (OR)","paramValue":"3.43","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"4.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"27.25","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"10.85","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"10.5","value":"4.7"},{"groupId":"OG001","lowerLimit":"9.3","upperLimit":"22.7","value":"14.8"},{"groupId":"OG002","lowerLimit":"28.8","upperLimit":"43.3","value":"35.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"108"},{"groupId":"OG002","value":"165"}],"units":"Participants"}],"description":"PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants with baseline PRO measures for EB hair loss ≥2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}